Agilis Robotics drops mega news with sick advancements in fancy Endoluminal Surgery Tech

Brace yourselves ’cause Agilis Robotics is straight-up changing the game in endoluminal surgery. They’ve cracked the code on mini robotic instruments that are flexin’ their muscles in tricky anatomies. Surgeons now got mad skills to slice and dice tissues with precision, all through natural orifices. And get this – it’s all vibing with the regular endoscope’s hospitals use, making it easy peasy for the pros.

The whole setup includes a boss cart, a chill control console, and throwaway robotic arms for top-notch performance and cleanliness. And guess what? It’s a budget-friendly move, costing less than 20% of the other fancy robotic systems out there. That means less money upfront for hospitals and more cash in their pockets – talk about a win-win.

With the world going crazy for endoluminal surgeries, Agilis Robotics is on point. Cancer screenings and spotting early tumours are on the rise, with over 3.5 million new GI cancer cases and 690k bladder cancer cases globally each year. Agilis Robotics is all set to take over the endoluminal surgery scene, giving patients quick and effective treatment for those early-stage troubles.

These peeps started as a spin-off from The University of Hong Kong and bagged a cool HKD 90 million from private investors. They’re using that cash flow for more development and getting ready to hit the clinical trials scene after acing six live animal studies in Hong Kong and Shenzhen. The results? Straight-up promising for accuracy, safety, and effectiveness.

Hold tight because the first-in-human trials are coming in hot, set for the first half of 2024. Agilis Robotics ain’t slacking off either – they’re gearing up for the FDA and NMPA nods, a massive step toward getting this game-changing tech out there.

CFO Hui Ka-Ming, a pro in investing and pre-profit biotech companies, is stoked about Agilis Robotics rocking the HKEX ‘Chapter 18A’ list. He’s all about that success and knows the deal with keeping it cost-effective, marketable, and with killer potential – making investors and hospitals the real Most Valuable Players.